Certolizumab Market Size, Share, and Industry Analysis, By Type (Biologics and Biosimilars), By Application (Crohn’s Disease, Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis, and Others), By Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, and Online Pharmacies), and Regional Forecast, 2025-2032

Certolizumab is a biological drug that is used for the treatment of moderate-to-severe rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and Crohn's disease. It works by blocking a protein called tumor necrosis factor (TNF) that causes inflammation in the body. Certolizumab comes as a subcutaneous injection that is typically given every 2-4 weeks. Patients need to be screened for other conditions, such as tuberculosis, hepatitis, and other infections, before starting certolizumab. It is often used in combination with other medications, such as methotrexate.

The market growth is primarily attributed to the rising prevalence of chronic diseases such as Crohn's disease globally. Certolizumab has been shown to induce endoscopic improvement in Crohn's disease, which is expected to boost its adoption, driving the market growth during the forecast period.

• For instance, as per the article published by the Center for Disease Control and Prevention in April 2023, around 7 million individuals were suffering from inflammatory bowel disease (IBD). The main types of IBD include Crohn’s disease and ulcerative colitis.

Moreover, certolizumab (Cimzia) is becoming increasingly popular as a treatment for autoimmune disorders such as psoriatic arthritis and rheumatoid arthritis worldwide. In addition, it has well-established usage in terms of treatment of ankylosing spondylitis. Ongoing clinical trials and research projects are examining the drug's effectiveness in different inflammatory disorders, leading to the diversification of its applications. This is expected to surge the market growth in the forthcoming years. In addition, the rising geriatric population globally is also expected to surge the market growth during the forecast period. Aged individuals are more susceptible to articular degeneration and inflammation of joints due to rheumatoid arthritis. This is projected to increase the utilization of certolizumab during the projection period.

The COVID-19 pandemic significantly impacted the global certolizumab market in 2020. The adoption of certolizumab was particularly triggered due to the increased use of certolizumab pegol for COVID-19-induced psoriatic arthritis. This stabilized the market growth in 2020 despite a decrease in the number of patient visits for autoimmune diseases. Furthermore, as the prevalence of inflammatory diseases is anticipated to continue to expand during the forecast period, it is projected to contribute to the growth of the market during the forecast period.

Segmentation

Key Insights

The report covers the following key insights:

• Incidence of Key Diseases, By Key Countries/Region, 2023
• Overview: Regulatory Scenario By Key Countries
• Pipeline Analysis By Key Players
• Key Industry Developments (Mergers, Acquisitions, Partnerships)
• Impact of COVID-19 on the Market

Analysis by Type

Based on the type, the market is bifurcated into biologics and biosimilars. The biologics segment is projected to account for a significant share of the global certolizumab market during the forecast period. The growth of this segment is attributed to its rising use of CIMZIA in several inflammatory conditions, as it is the only marketed biologic currently available in the market. Furthermore, the high burden of these diseases worldwide is projected to boost segmental growth in the forthcoming years.

• For instance, CIMZIA (certolizumab pegol) is one of the key U.S. FDA-approved biologics that is used for the treatment of Crohn’s disease, rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis.

On the other hand, the biosimilar segment is anticipated to grow at a substantial CAGR during the forecast period. The segment's growth is attributed to the growing emphasis of key players on the development of certolizumab’s biosimilars. Moreover, the expiration of patents for this drug in various countries is stimulating the key players to accelerate the development of biosimilars, which is expected to drive segmental growth in the forthcoming years.

Regional Analysis

To gain extensive insights into the market, Download for Customization

The global market is geographically segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America is expected to hold a significant share of the certolizumab market during the forecast period. The market growth of the region is attributed to the rising incidence of inflammatory diseases such as rheumatoid arthritis, which is increasing the demand for the use of certolizumab, encouraging the key players to increase its availability. Moreover, the research and development initiatives for biosimilars of certolizumab in the region are anticipated to fuel the market growth during the forecast period.

• For instance, an article published by UpToDate, Inc. in February 2024 estimated the prevalence of rheumatoid arthritis in the U.S. and northern European countries to be approximately 40 per 100,000 persons.

Asia Pacific is projected to grow significantly during the forecast timeframe. The region's growth is mainly attributed to the high patient pool of rheumatoid arthritis and ankylosing spondylitis seeking treatment of these diseases. This represents a significant opportunity for certolizumab as a treatment option to improve patient outcomes in the region. Moreover, the increasing awareness of these diseases is also expected to boost the demand for certolizumab, fueling the region’s market growth in the forthcoming years.

Key Players Covered

The market consists of significant players, such as UCB S.A., Biogen, Xbrane Biopharma, Paras Biopharmaceuticals, and others. Key players' focus on developing biosimilars of certolizumab is expected to boost their revenue during the forecast period.

Key Industry Developments

• In February 2022, Biogen and Xbrane entered into a commercialization and license agreement for a biosimilar candidate, Xcimzane, referencing Cimzia (UCB S.A.; certolizumab pegol), to treat rheumatologic conditions.
• In July 2020, UCB S.A. and Ferring Group entered into a co-promotion agreement for the commercialization of prefilled syringe formulation of CIMZIA in the U.S. for the treatment of Crohn’s disease (CD).